Linda A Dimeglio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6239871/publications.pdf

Version: 2024-02-01

237 papers

16,393 citations

18482 62 h-index 120 g-index

249 all docs 249 docs citations

times ranked

249

14035 citing authors

#	Article	IF	Citations
1	Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal of Diabetes Science and Technology, 2023, 17, 976-987.	2.2	8
2	Incident diabetes complications among women with type 1 diabetes based on parity. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 4629-4634.	1.5	1
3	Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric <scp>MiniMed</scp> ™ <scp>670G</scp> system trial. Pediatric Diabetes, 2022, 23, 324-329.	2.9	41
4	COVID-19 Pandemic Effects on Caregivers of Youth With Type 1 Diabetes: Stress and Self-Efficacy. Diabetes Spectrum, 2022, 35, 461-468.	1.0	3
5	Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health, 2022, 4, e245-e255.	12.3	33
6	Women in diabetes research: stepping towards equity. Lancet Diabetes and Endocrinology, the, 2022, 10, 236-238.	11.4	0
7	Development and delivery of a brief family behavioral intervention to support continuous glucose monitor use in young children with type 1 diabetes. Pediatric Diabetes, 2022, 23, 792-798.	2.9	5
8	Response to Comment on Dunne et al. The Women's Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes Care 2021;44:1734–1743. Diabetes Care, 2022, 45, e99-e99.	8.6	0
9	Editorial Cycles and Continuity of <i>Diabetes Care</i> . Diabetes Care, 2022, 45, 1493-1494.	8.6	O
10	Radiologists' Diagnostic Performance in Differentiation of Rickets and Classic Metaphyseal Lesions on Radiographs: A Multicenter Study. American Journal of Roentgenology, 2022, 219, 962-972.	2.2	4
11	A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. Diabetes Care, 2021, 44, 464-472.	8.6	53
12	Bone mineral acquisition in utero and during infancy and childhood., 2021,, 875-909.		0
13	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science Translational Medicine, 2021, 13, .	12.4	142
14	57437 Effects of Prebiotics on the Gut Microbiome Profile, Beta-cell Function and Immune Markers in Newly-Diagnosed Type 1 Diabetes. Journal of Clinical and Translational Science, 2021, 5, 38-38.	0.6	1
15	Hypocalcemia in a 15 Year Old With New Onset Type 2 Diabetes Mellitus. Journal of the Endocrine Society, 2021, 5, A200-A200.	0.2	O
16	Dasiglucagon, a nextâ€generation readyâ€toâ€use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatric Diabetes, 2021, 22, 734-741.	2.9	26
17	COVID-19 and Type 1 Diabetes: Addressing Concerns and Maintaining Control. Diabetes Care, 2021, 44, 1924-1928.	8.6	15
18	The Women's Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes Care, 2021, 44, 1734-1743.	8.6	15

#	Article	IF	Citations
19	The Women's Leadership Gap in Diabetes: A Call for Equity and Excellence. Diabetes, 2021, 70, 1623-1633.	0.6	10
20	100 years of insulin: celebrating the past, present and future of diabetes therapy. Nature Medicine, 2021, 27, 1154-1164.	30.7	94
21	Mental Health Matters: Limited Support Remains a Barrier to Optimal Care for Youth With Diabetes. Canadian Journal of Diabetes, 2021, 45, 379-380.	0.8	2
22	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia, 2021, 64, 2432-2444.	6.3	8
23	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 502-514.	11.4	53
24	The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence. Diabetes Care, 2021, 44, 301-312.	8.6	32
25	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care, 2021, 44, 8-10.	8.6	8
26	IL-6 receptor blockade does not slow \hat{l}^2 cell loss in new-onset type 1 diabetes. JCI Insight, 2021, 6, .	5.0	25
27	Growth patterns of uninfected children born to women living with perinatally-versus non-perinatally-acquired HIV. Aids, 2021, Publish Ahead of Print, .	2.2	0
28	"l'm essentially his pancreas†Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes, 2020, 21, 377-383.	2.9	57
29	Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care, 2020, 43, e1-e2.	8.6	59
30	The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia, 2020, 63, 588-596.	6.3	58
31	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	8.6	220
32	Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. Clinical Pediatrics, 2020, 59, 1080-1085.	0.8	6
33	Changes in Device Uptake and Glycemic Control among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange. Journal of Diabetes Science and Technology, 2020, 15, 193229682097212.	2.2	8
34	COVID-19 and Children With Diabetesâ€"Updates, Unknowns, and Next Steps: First, Do No Extrapolation. Diabetes Care, 2020, 43, 2631-2634.	8.6	60
35	The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4393-e4406.	3.6	4
36	Fractures in children and adolescents living with perinatally acquired HIV. Bone, 2020, 139, 115515.	2.9	1

#	Article	IF	CITATIONS
37	Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study. Diabetic Medicine, 2020, 37, 1308-1315.	2.3	16
38	Sources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children &It8 Years Old with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 697-700.	4.4	11
39	Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2032-e2038.	3.6	26
40	Putting Continuous Glucose Monitoring to Work for People With Type 1 Diabetes. Diabetes Care, 2020, 43, 19-21.	8.6	17
41	Strategies That Adolescents With Type 1 Diabetes Use in Relation to Exercise. Clinical Diabetes, 2020, 38, 266-272.	2.2	3
42	180-OR: Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia in Children with Diabetes. Diabetes, 2020, 69, 180-OR.	0.6	3
43	99-OR: An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D). Diabetes, 2020, 69, 99-OR.	0.6	0
44	1616-P: Stimulated $\tilde{A}\ddot{Y}$ -Cell Response Is Unaltered in Adult Autoantibody (AB) Negative Relatives of Individuals with Type 1 Diabetes (T1D). Diabetes, 2020, 69, .	0.6	0
45	10-OR: Implementing CGM with a Family Behavioral Intervention (FBI) Reduces Psychosocial Distress in Parents of Children 2-8 Y/O: A Pre–Post Comparison. Diabetes, 2020, 69, 10-OR.	0.6	6
46	67-OR: Benefit of Reduced Hypoglycemia with Continuous Glucose Monitoring (CGM) Is Sustained through 12 Months among Young Children with Type 1 Diabetes (T1D). Diabetes, 2020, 69, .	0.6	6
47	749-P: Parents' Psychosocial Outcomes from the Strategies to Encourage New CGM Use in Early Childhood (SENCE) Trial at 12 Months. Diabetes, 2020, 69, .	0.6	1
48	890-P: Durability of Continuous Glucose Monitoring (CGM) Use in Young Children, Teens, and Young Adults with Type 1 Diabetes (T1D). Diabetes, 2020, 69, 890-P.	0.6	1
49	Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care, 2019, 42, 192-199.	8.6	27
50	Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 493-498.	4.4	87
51	Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring. Diabetic Medicine, 2019, 36, 1508-1510.	2.3	4
52	Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes. Molecular Metabolism, 2019, 27, S129-S138.	6.5	12
53	State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology and Therapeutics, 2019, 21, 66-72.	4.4	1,332
54	Optimizing the use of continuous glucose monitoring in young children with type 1 diabetes with an adaptive study design and multiple randomizations. Contemporary Clinical Trials, 2019, 82, 60-65.	1.8	1

#	Article	IF	CITATIONS
55	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 603-613.	27.0	584
56	Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol. BMJ Open, 2019, 9, e027856.	1.9	14
57	Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258–264. Diabetes Care, 2019, 42, e85-e86.	8.6	5
58	Associations of HbA1c with the timing of Câ€peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes. Pediatric Diabetes, 2019, 20, 408-413.	2.9	3
59	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.6	80
60	Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study. Journal of Pediatrics, 2019, 209, 116-124.e4.	1.8	39
61	Sweet Bones. , 2019, , 425-441.		3
62	Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care, 2019, 42, 2228-2236.	8.6	18
63	Markers of Bone Mineral Metabolism and Cardiac Structure and Function in Perinatally HIV-Infected and HIV-Exposed but Uninfected Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 238-246.	2.1	3
64	Analysis of serum Hsp90 as a potential biomarker of \hat{l}^2 cell autoimmunity in type 1 diabetes. PLoS ONE, 2019, 14, e0208456.	2.5	15
65	Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care, 2019, 42, 258-264.	8.6	82
66	1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange. Diabetes, 2019, 68 , .	0.6	3
67	1681-P: Polyendocrinopathy in Type 1 Diabetes: A Transatlantic Comparison. Diabetes, 2019, 68, .	0.6	20
68	85-OR: Modifiers of C-Peptide Change during the Progression to Type 1 Diabetes (T1D) in the TrialNet Pathway to Prevention Study. Diabetes, 2019, 68, .	0.6	0
69	230-LB: Intraindividual Variability of Measures of Beta-Cell Response. Diabetes, 2019, 68, .	0.6	0
70	187-LB: Glucose Response Curve (GRC) Shapes in Mixed Meal Tolerance Tests (MMTTs) and Prediction of Response to Intervention in the TrialNet New-Onset Clinical Trials. Diabetes, 2019, 68, 187-LB.	0.6	0
71	1729-P: Circadian Patterns of Autoimmune Components in the Blood of Persons with Type 1 Diabetes: Implications for the Timing of Blood Sampling. Diabetes, 2019, 68, 1729-P.	0.6	0
72	2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity. Diabetes, 2019, 68, 2418-PUB.	0.6	0

#	Article	IF	Citations
73	1354-P: Novel Telehealth Support Intervention for Young Children Using HCL. Diabetes, 2019, 68, .	0.6	О
74	1369-P: Continuous Glucose Monitoring Interventions in Toddlers with Type 1 Diabetes (T1D). Diabetes, 2019, 68, 1369-P.	0.6	0
75	1343-P: A Comparison of C-Peptide and Glucose Responses between Children and Adolescents Who Progress to Type 1 Diabetes (T1D). Diabetes, 2019, 68, .	0.6	0
76	Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1966-1976.	3.6	10
77	Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia, 2018, 61, 1124-1134.	6.3	112
78	Changes in insulin sensitivity over time and associated factors in HIV-infected adolescents. Aids, 2018, 32, 613-622.	2.2	20
79	Prevalence of Nephrocalcinosis in Pseudohypoparathyroidism: Is Screening Necessary?. Journal of Pediatrics, 2018, 199, 263-266.	1.8	8
80	Nighttime is the worst time: Parental fear of hypoglycemia in young children with type 1 diabetes. Pediatric Diabetes, 2018, 19, 114-120.	2.9	107
81	Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired <scp>HIV</scp> on older protease inhibitors: results from the Pediatric <scp>HIV</scp> / <scp>AIDS</scp> Cohort Study. HIV Medicine, 2018, 19, 175-183.	2.2	6
82	2261. Phosphaturia in HIV-Exposed Uninfected Neonates Associated With Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy. Open Forum Infectious Diseases, 2018, 5, S669-S669.	0.9	0
83	Determinants of fracture in adults with type 1 diabetes in the USA: Results from the T1D Exchange Clinic Registry. Journal of Diabetes and Its Complications, 2018, 32, 1006-1011.	2.3	31
84	ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatric Diabetes, 2018, 19, 105-114.	2.9	464
85	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves \hat{I}^2 -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	8.6	114
86	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care, 2018, 41, 1887-1894.	8.6	104
87	Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, 576-584.	4.4	22
88	Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. Journal of Diabetes and Its Complications, 2018, 32, 961-965.	2.3	35
89	Type 1 diabetes. Lancet, The, 2018, 391, 2449-2462.	13.7	888
90	The influence of body mass index and age on Câ€peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trialâ€type 1. Pediatric Diabetes, 2018, 19, 403-409.	2.9	17

#	Article	IF	Citations
91	\hat{l}^2 Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight, 2018, 3, .	5.0	62
92	Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network. Diabetes, 2018, 67, .	0.6	15
93	Bone Health Laboratory Assessments. , 2018, , 93-109.		o
94	The Influence of Parental Type 1 Diabetes (T1D) on the Progression to T1D in Autoantibody-Positive Offspring. Diabetes, 2018, 67, 1693-P.	0.6	0
95	Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D). Diabetes, 2018, 67, 15-LB.	0.6	O
96	Impact of Target HbA1c Change in Pediatric Participants in the T1D Exchange Clinic Registry. Diabetes, 2018, 67, .	0.6	0
97	Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. Bone, 2017, 97, 287-292.	2.9	50
98	Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation. Pediatric Infectious Disease Journal, 2017, 36, 189-197.	2.0	22
99	Delay in sexual maturation in perinatally HIV-infected youths is mediated by poor growth. Aids, 2017, 31, 1333-1341.	2.2	27
100	Insulin Pump Use in Young Children with Type 1 Diabetes: Sociodemographic Factors and Parent-Reported Barriers. Diabetes Technology and Therapeutics, 2017, 19, 363-369.	4.4	58
101	Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A _{1c} Levels. Annals of Internal Medicine, 2017, 167, 95.	3.9	231
102	Health Care Transition Preparation and Experiences in a U.S. National Sample of Young Adults With Type 1 Diabetes. Diabetes Care, 2017, 40, 317-324.	8.6	82
103	Managing diabetes in preschool children. Pediatric Diabetes, 2017, 18, 499-517.	2.9	73
104	Sleep in children with type 1 diabetes and their parents in the T1D Exchange. Sleep Medicine, 2017, 39, $108-115$.	1.6	78
105	Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries. Diabetes Care, 2017, 40, e139-e140.	8.6	44
106	Associations of Low Vitamin D and Elevated Parathyroid Hormone Concentrations With Bone Mineral Density in Perinatally HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 33-42.	2.1	10
107	Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 980-987.	2.2	38
108	Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3111-3123.	3.6	170

#	Article	IF	CITATIONS
109	Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry. Journal of Diabetes Science and Technology, 2017, 11, 224-232.	2.2	52
110	Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care, 2016, 39, 264-270.	8.6	86
111	Elevations in the Fasting Serum Proinsulin–to–C-Peptide Ratio Precede the Onset of Type 1 Diabetes. Diabetes Care, 2016, 39, 1519-1526.	8.6	106
112	Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatric Diabetes, 2016, 17, 237-243.	2.9	11
113	Effects of Frequency of Sensor-Augmented Pump Use on HbA1cand C-Peptide Levels in the First Year of Type 1 Diabetes. Diabetes Care, 2016, 39, e61-e62.	8.6	5
114	The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. Diabetologia, 2016, 59, 1186-1195.	6.3	36
115	Autoimmune Diseases in Children and Adults With Type 1 Diabetes From the T1D Exchange Clinic Registry. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4931-4937.	3.6	75
116	Seven great achievements in pediatric research in the past 40 y. Pediatric Research, 2016, 80, 330-337.	2.3	19
117	Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care, 2016, 39, 1664-1670.	8.6	112
118	Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264–270. Diabetes Care, 2016, 39, e193-e194.	8.6	13
119	Bone Densitometry in Children and Adolescents. Pediatrics, 2016, 138, .	2.1	117
120	HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. Diabetes, 2016, 65, 1109-1119.	0.6	48
121	Understanding Career Success and Its Contributing Factors for Clinical and Translational Investigators. Academic Medicine, 2016, 91, 570-582.	1.6	33
122	Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. Hormone Research in Paediatrics, 2016, 85, 83-106.	1.8	158
123	Advances in the Classification and Treatment of Osteogenesis Imperfecta. Current Osteoporosis Reports, 2016, 14, 1-9.	3.6	73
124	Special article: 2014 Pediatric Clinical Trials Forum. Pediatric Research, 2016, 79, 662-669.	2.3	17
125	Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 394-415.	3.6	774
126	Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care, 2016, 39, 555-562.	8.6	91

#	Article	IF	CITATIONS
127	Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes. Translational Research, 2016, 168, 96-106.e1.	5.0	56
128	Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index. Acta Diabetologica, 2016, 53, 271-277.	2.5	55
129	Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. Diabetes Care, 2015, 38, 1975-1985.	8.6	68
130	Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care, 2015, 38, 971-978.	8.6	1,082
131	Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. Diabetes Care, 2015, 38, 476-481.	8.6	187
132	Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. Pediatrics, 2015, 135, 424-434.	2.1	282
133	Elevations in Circulating Methylated and Unmethylated Preproinsulin DNA in New-Onset Type 1 Diabetes. Diabetes, 2015, 64, 3867-3872.	0.6	80
134	Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. Clinical Infectious Diseases, 2015, 61, 996-1003.	5.8	97
135	Immune Intervention for Type 1 Diabetes, 2013–2014. Diabetes Technology and Therapeutics, 2015, 17, S-80-S-87.	4.4	2
136	Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the UnitedÂStates. Journal of Pediatrics, 2015, 167, 627-632.e4.	1.8	150
137	Bone Density in Children with Single Ventricle Physiology. Pediatric Cardiology, 2015, 36, 779-785.	1.3	16
138	Alternate Approaches for Pediatric Type 1 Diabetes Drug Development and Potential Regulatory Approval: A Perspective: Table 1. Diabetes Care, 2015, 38, 1986-1991.	8.6	4
139	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2015, 17, S-96-S-108.	4.4	1
140	Commentary: Launch of a Quality Improvement Network for Evidence-Based Management of Uncommon Pediatric Endocrine Disorders: Turner Syndrome as a Prototype. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1234-1236.	3.6	13
141	Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2015, 314, 2241.	7.4	155
142	A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History. Diabetes Care, 2015, 38, 271-276.	8.6	59
143	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. Journal of Clinical Investigation, 2015, 125, 3285-3296.	8.2	228
144	The Relationship of Worry About Hypoglycemia With Diabetes-specific and Typical Youth Behavior Among Emerging Adults With Type 1 Diabetes. The Diabetes Educator, 2014, 40, 533-542.	2.5	27

#	Article	IF	CITATIONS
145	Microvascular and macrovascular complications in children and adolescents. Pediatric Diabetes, 2014, 15, 257-269.	2.9	140
146	Aggregate Risk of Cardiovascular Disease Among Adolescents Perinatally Infected With the Human Immunodeficiency Virus. Circulation, 2014, 129, 1204-1212.	1.6	42
147	Racial Differences in Sensitivity of Blood Pressure to Aldosterone. Hypertension, 2014, 63, 1212-1218.	2.7	98
148	Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment. Diabetes Care, 2014, 37, 1069-1075.	8.6	168
149	003 – Autonomy of Children With Type I Diabetes on Insulin Pump Therapy. Journal of Pediatric Nursing, 2014, 29, 292.	1.5	0
150	Metabolic Bone Diseases. , 2014, , 317-344.		6
151	Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Translational Research, 2014, 164, 110-121.	5.0	58
152	Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatric Diabetes, 2014, 15, 564-572.	2.9	110
153	Calcium and Phosphate. , 2014, , 261-282.		9
154	Promoting Education, Mentorship, and Support for Pediatric Research. Pediatrics, 2014, 133, 943-949.	2.1	18
155	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2014, 16, S-100-S-109.	4.4	0
156	Diabetesâ€Related Quality of Life and the Demands and Burdens of Diabetes Care Among Emerging Adults With Type 1 Diabetes in the Year After High School Graduation. Research in Nursing and Health, 2014, 37, 399-408.	1.6	20
157	Immune Intervention for Type 1 Diabetes, 2012–2013. Diabetes Technology and Therapeutics, 2014, 16, S-85-S-91.	4.4	1
158	Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease. Bone, 2014, 68, 6-10.	2.9	18
159	Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6\AA years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia, 2014, 57, 1578-1585.	6.3	147
160	Bone Densitometry in Infants and Young Children: The 2013 ISCD Pediatric Official Positions. Journal of Clinical Densitometry, 2014, 17, 243-257.	1,2	78
161	Initial findings: primary diabetes care responsibility among emerging adults with type 1 diabetes post high school and move out of parental home. Child: Care, Health and Development, 2013, 39, 61-68.	1.7	28
162	Bone Mineral Acquisition in Utero and During Infancy and Childhood., 2013,, 977-1015.		2

#	Article	IF	CITATIONS
163	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 284-294.	11.4	169
164	Diabetes Technology and Treatment in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2013, 15, S-107-S-116.	4.4	3
165	Incidence and Characteristics of Pseudoprecocious Puberty Because of Severe Primary Hypothyroidism. Journal of Pediatrics, 2013, 162, 637-639.	1.8	41
166	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	13.7	301
167	The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups $<$ Substituting Substitution (Diabetes Technology) and Therapeutics, 2013, 15, 401-408.	4.4	17
168	Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. Aids, 2013, 27, 1959-1970.	2.2	58
169	Effectiveness of Early Intensive Therapy on \hat{I}^2 -Cell Preservation in Type 1 Diabetes. Diabetes Care, 2013, 36, 4030-4035.	8.6	58
170	Readiness for Living Independently Among Emerging Adults With Type 1 Diabetes. The Diabetes Educator, 2013, 39, 92-99.	2.5	25
171	Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care, 2013, 36, 2035-2037.	8.6	360
172	Long-Term Glycemic Control as a Result of Initial Education for Children With New Onset Type 1 Diabetes. The Diabetes Educator, 2013, 39, 187-194.	2.5	7
173	Bone mineral density in children and adolescents with perinatal HIV infection. Aids, 2013, 27, 211-220.	2.2	67
174	Safety of tenofovir use during pregnancy. Aids, 2012, 26, 1151-1159.	2.2	118
175	The Relationship Between Components of the Metabolic Syndrome and Bone Health. , 2012, , 183-198.		1
176	Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in <scp>HIV</scp> â€infected children. HIV Medicine, 2012, 13, 264-275.	2.2	58
177	Wasting Diseases and Metabolic Impact on Bone: Emerging Therapeutics and Treatment Options. , 2012, , 179-195.		0
178	The utility of hemoglobin A1c at diagnosis for prediction of future glycemic control in children with type 1 diabetes. Diabetes Research and Clinical Practice, 2011, 92, 65-68.	2.8	26
179	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 412-419.	13.7	493
180	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet, The, 2011, 378, 319-327.	13.7	325

#	Article	IF	CITATIONS
181	Insulin dose changes in children attending a residential diabetes camp. Diabetic Medicine, 2011, 28, 480-486.	2.3	18
182	Natural History of Idiopathic Diabetes Insipidus. Journal of Pediatrics, 2011, 159, 566-570.	1.8	25
183	Gestational diabetes mellitus alters maternal and neonatal circulating endothelial progenitor cell subsets. American Journal of Obstetrics and Gynecology, 2011, 204, 254.e8-254.e15.	1.3	37
184	Calcium, dairy products, and energy balance in overweight adolescents: a controlled trial. American Journal of Clinical Nutrition, 2011, 94, 1163-1170.	4.7	20
185	Contracting and Monitoring Relationships for Adolescents with Type 1 Diabetes: A Pilot Study. Diabetes Technology and Therapeutics, 2011, 13, 543-549.	4.4	42
186	Intensified Effect of Adiposity on Blood Pressure in Overweight and Obese Children. Hypertension, 2011, 58, 818-824.	2.7	131
187	Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. American Journal of Clinical Nutrition, 2011, 94, 1485-1495.	4.7	54
188	Factors Associated with Insulin Resistance among Children and Adolescents Perinatally Infected with HIV-1 in the Pediatric HIV/AIDS Cohort Study. Hormone Research in Paediatrics, 2011, 76, 386-391.	1.8	55
189	Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 633-40.	0.9	2
190	Using a Cell Phone-Based Glucose Monitoring System for Adolescent Diabetes Management. The Diabetes Educator, 2011, 37, 59-66.	2.5	59
191	Endothelial Abnormalities in Adolescents with Type 1 Diabetes: A Biomarker for Vascular Sequelae?. Journal of Pediatrics, 2010, 157, 540-546.	1.8	37
192	Calcium requirements and metabolism in Chinese-American boys and girls. Journal of Bone and Mineral Research, 2010, 25, 1842-1849.	2.8	44
193	Daily Supplementation with 25 µg Cholecalciferol Does Not Increase Calcium Absorption or Skeletal Retention in Adolescent Girls with Low Serum 25-Hydroxyvitamin D. Journal of Nutrition, 2010, 140, 2139-2144.	2.9	42
194	Ocular Manifestations of Juvenile Paget Disease. JAMA Ophthalmology, 2010, 128, 698.	2.4	29
195	Vitamin D and cardiovascular disease risk in children. Nature Reviews Endocrinology, 2010, 6, 12-13.	9.6	1
196	Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1846-1850.	3.6	138
197	The Transition to Young Adulthood: Diabetes-Related Quality of Life - Worry Among High School Seniors with Type 1 Diabetes. Journal of Adolescent Health, 2010, 46, S12.	2.5	0
198	Conjugated Oral versus Transdermal Estrogen Replacement in Girls with Turner Syndrome: A Pilot Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2009-2014.	3.6	103

#	Article	IF	CITATIONS
199	Hearing Loss in Children with Osteogenesis Imperfecta (OI) Treated with Bisphosphonates. Laryngoscope, 2009, 119, S134.	2.0	O
200	A randomized prospective study of insulin pump vs. insulin injection therapy in very young children with type 1 diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. Pediatric Diabetes, 2009, 10, 202-208.	2.9	42
201	Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD 2007 Pediatric Official Positions. Journal of Clinical Densitometry, 2008, 11, 22-28.	1.2	121
202	In Vitro Hyperglycemia or a Diabetic Intrauterine Environment Reduces Neonatal Endothelial Colony-Forming Cell Numbers and Function. Diabetes, 2008, 57, 724-731.	0.6	145
203	Vitamin D Status and Calcium Metabolism in Adolescent Black and White Girls on a Range of Controlled Calcium Intakes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3907-3914.	3.6	84
204	Hypocalcemia as a Presenting Feature of Celiac Disease in a Patient with DiGeorge Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 253-5.	0.9	4
205	Autosomal Dominant Osteopetrosis: Clinical Severity and Natural History of 94 Subjects with a Chloride Channel 7 Gene Mutation. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 771-778.	3.6	129
206	Acute Effects of Enteral Nutrition on Protein Turnover in Adolescents with Crohn Disease. Pediatric Research, 2007, 61, 356-360.	2.3	23
207	Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type la: A case report. Bone, 2007, 40, 1425-1428.	2.9	30
208	Premature Thelarche., 2007,, 169-188.		0
209	Calcium retention as a function of calcium intake in Asian adolescents. FASEB Journal, 2007, 21, A354.	0.5	0
210	Bisphosphonate therapy for fibrous dysplasia. Pediatric Endocrinology Reviews, 2007, 4 Suppl 4, 440-5.	1.2	12
211	Predictors of glycemic control on insulin pump therapy in children and adolescents with type I diabetes. Diabetes Research and Clinical Practice, 2006, 74, 217-221.	2.8	28
212	Presentation and clinical progression of pseudohypoparathyroidism with multi-hormone resistance and Albright hereditary osteodystrophy: A case series. Journal of Pediatrics, 2006, 149, 877-880.e1.	1.8	53
213	Brief Report: Initial Testing of Scales Measuring Parent and Adolescent Perceptions of Adolescents' Assumption of Diabetes Management. Journal of Pediatric Psychology, 2006, 32, 245-249.	2.1	9
214	Initial Management of Infants with Intersex Conditions in a Tertiary Care Center: A Cautionary Tale. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 191-2.	0.9	2
215	Two-Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta. Journal of Bone and Mineral Research, 2005, 21, 132-140.	2.8	103
216	Bone Mineral Accrual and Low Bone Mass: A Pediatric Perspective. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 281-289.	5.7	11

#	Article	IF	Citations
217	Parent and Adolescent Versions of the Diabetes-Specific Parental Support for Adolescents' Autonomy Scale: Development and Initial Testing. Journal of Pediatric Psychology, 2005, 30, 257-271.	2.1	33
218	A Comparison of Oral and Intravenous Bisphosphonate Therapy for Children with Osteogenesis Imperfecta. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 43-53.	0.9	38
219	Craniofacial features with growth hormone treatment. Journal of Pediatrics, 2005, 146, 295.	1.8	1
220	Selecting families for successful insulin pump therapy. Journal of Pediatrics, 2005, 146, 713.	1.8	3
221	Severe Infantile Hypercalcemia Associated With Williams Syndrome Successfully Treated With Intravenously Administered Pamidronate. Pediatrics, 2004, 114, 1091-1095.	2.1	50
222	Preschoolers Are Not Miniature Adolescents: A Comparison of Insulin Pump Doses in Two Groups of Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 865-70.	0.9	20
223	Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone, 2004, 35, 1038-1045.	2.9	84
224	Craniofacial and acral growth responses in growth hormone-deficient children treated with growth hormone. Journal of Pediatrics, 2004, 144, 437-443.	1.8	25
225	A randomized, controlled study of insulin pump therapy in diabetic preschoolers. Journal of Pediatrics, 2004, 145, 380-384.	1.8	158
226	Assay Interference Leading to Misdiagnosis of Central Precocious Puberty. Endocrine, 2003, 20, 195-200.	2.2	13
227	Massive ischemic intestinal necrosis at the onset of diabetes mellitus with ketoacidosis in a three-year-old girl. Journal of Pediatric Surgery, 2003, 38, 1537-1539.	1.6	25
228	Autoimmune Thyroid Dysfunction in Children with Type 1 Diabetes Mellitus: Screening Guidelines Based on a Retrospective Analysis. Journal of Pediatric Endocrinology and Metabolism, 2003, 16, 1111-7.	0.9	23
229	Difference in Bone Mass between Black and White American Children: Attributable to Body Build, Sex Hormone Levels, or Bone Turnover?. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 642-649.	3.6	50
230	Genotype-phenotype correlation in inherited severe insulin resistance. Human Molecular Genetics, 2002, 11, 1465-1475.	2.9	136
231	Low Hemoglobin Levels in Children With in Idiopathic Growth Hormone Deficiency. Endocrine, 2002, 18, 135-136.	2.2	14
232	A Missense Mutation Encoding Cys67 → Gly in Neurophysin II Is Associated with Early Onset Autosomal Dominant Neurohypophyseal Diabetes Insipidus. Molecular Genetics and Metabolism, 2001, 72, 39-44.	1.1	25
233	Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: A meta-analysis. Journal of Pediatrics, 2001, 138, 26-32.	1.8	168
234	Hypophosphatemic rickets., 2001, 2, 165-173.		17

#	Article	IF	CITATIONS
235	DISORDERS OF PHOSPHATE METABOLISM. Endocrinology and Metabolism Clinics of North America, 2000, 29, 591-609.	3.2	38
236	The Prospect for a Reasonable Adult Height in Patients with 21-hydroxylase Deficiency Is Dismalor Is it?. Pediatric Research, 1999, 45, 87A-87A.	2.3	0
237	Variations on a theme: testis-derived neuropeptide hormones. European Journal of Endocrinology, 1998, 139, 361-362.	3.7	4